Key Takeaways
- • Penumbra shares declined as much as 8% on November 10, 2020, immediately following Gabriel Grego's announcement of a new short position in the medical device manufacturer, though the stock recovered to trade down 0.1% at $242.11 by close.
- • Gabriel Grego, managing partner and chief investment officer of Quintessential Capital Management (QCM), a New York-based long/short equity hedge fund, disclosed his short thesis on the California-based company during an appearance on investor Carson Block's short-selling show "The Chopping Block" on Zer0es.tv.
- • Grego's short thesis centers on alleged failings of Penumbra's Jet 7 Xtra Flex catheter used in stroke treatment procedures, with concerns centered on product safety and efficacy claims.
- • Grego has an established track record of successful activist short campaigns; his 2018 short of cannabis company Aphria prompted an intraday decline of as much as 20%, establishing him as a notable market mover in activist short-selling circles.
- • Penumbra declined to address specific allegations, referring investors instead to the company's October 28 and November 2, 2020 earnings releases, call transcripts, and SEC filings.
Summary
Gabriel Grego, the prominent short-seller and managing partner of Quintessential Capital Management, initiated a new bearish position targeting Penumbra, the California-based medical device manufacturer, triggering an immediate 8% intraday decline in the company's share price on November 10, 2020. Grego announced the short position during an appearance on "The Chopping Block," a short-selling focused program hosted by activist investor Carson Block on Zer0es.tv. The stock experienced sharp selling pressure following the announcement but recovered substantially by market close, trading down only 0.1% at $242.11.
Grego's short thesis focuses on alleged deficiencies in Penumbra's Jet 7 Xtra Flex catheter, a device marketed for use in stroke patient treatment. His stated concerns center on safety issues and what he characterizes as misleading representations to physicians regarding the product's performance and clinical utility. The specifics of Grego's detailed findings were not disclosed in available sources, though his public criticism was sufficient to trigger significant selling pressure in the stock.
Penumbra's management declined to engage directly with the allegations, instead directing investors to consult the company's most recent earnings disclosures and SEC filings from October 28 and November 2, 2020. This defensive posture is standard practice for companies facing activist short campaigns, allowing legal teams to control messaging through official regulatory channels rather than reactive commentary.
Grego's track record in activist short-selling lends credibility to his position in institutional markets. Most notably, his 2018 short campaign against Canadian cannabis company Aphria precipitated a single-day stock decline of as much as 20%, demonstrating his ability to move markets and influence investor sentiment. His previous short targets have included UK software firm Globo Plc, Greek jewelry company Folli Follie, Italian bioplastics company Bio-on, and streaming platform Akazoo, establishing Grego as a recognized and often consequential voice in activist short-selling circles.
Grego's short thesis focuses on alleged deficiencies in Penumbra's Jet 7 Xtra Flex catheter, a device marketed for use in stroke patient treatment. His stated concerns center on safety issues and what he characterizes as misleading representations to physicians regarding the product's performance and clinical utility. The specifics of Grego's detailed findings were not disclosed in available sources, though his public criticism was sufficient to trigger significant selling pressure in the stock.
Penumbra's management declined to engage directly with the allegations, instead directing investors to consult the company's most recent earnings disclosures and SEC filings from October 28 and November 2, 2020. This defensive posture is standard practice for companies facing activist short campaigns, allowing legal teams to control messaging through official regulatory channels rather than reactive commentary.
Grego's track record in activist short-selling lends credibility to his position in institutional markets. Most notably, his 2018 short campaign against Canadian cannabis company Aphria precipitated a single-day stock decline of as much as 20%, demonstrating his ability to move markets and influence investor sentiment. His previous short targets have included UK software firm Globo Plc, Greek jewelry company Folli Follie, Italian bioplastics company Bio-on, and streaming platform Akazoo, establishing Grego as a recognized and often consequential voice in activist short-selling circles.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.